BVXV - BiondVax Pharmaceuticals Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.72
-0.06 (-1.04%)
At close: 12:42PM EDT
Stock chart is not supported by your current browser
Previous Close5.78
Open5.67
Bid5.67 x 1000
Ask11.80 x 1000
Day's Range5.67 - 5.72
52 Week Range4.60 - 7.85
Volume2,374
Avg. Volume5,359
Market Cap37.383M
Beta0.92
PE Ratio (TTM)N/A
EPS (TTM)-2.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Research15 days ago

    BVXV: Phase 3 Trial of M-001 Underway…

    BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has received feedback about the trial design and approval to conduct it from the European Medicines Agency (EMA).

  • BiondVax to Present at Influenza 2018 Oxford Conference
    PR Newswire16 days ago

    BiondVax to Present at Influenza 2018 Oxford Conference

    JERUSALEM, Sept. 4, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present at the Influenza 2018 Oxford conference at the University of Oxford. Joshua Phillipson, BiondVax's Business Development Manager, will provide an overview of the Company's clinical development achievements and plans, including the recently launched pivotal, clinical efficacy, Phase 3 trial.

  • BiondVax Announces Second Quarter 2018 Financial Results
    PR Newswire29 days ago

    BiondVax Announces Second Quarter 2018 Financial Results

    JERUSALEM , Aug. 22, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...

  • GlobeNewswirelast month

    Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MediciNova, ...

  • BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility
    PR Newswirelast month

    BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility

    JERUSALEM, Aug. 20, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today the company's relocation to a newly constructed mid-size commercial scale manufacturing facility in Jerusalem, Israel. Dr. Shimon Hassin, BiondVax's COO, commented, "BiondVax's new facility is custom-built for GMP manufacturing of our innovative flu vaccine candidate, which can be produced year-round and is designed to provide broad protection against influenza.

  • BiondVax Receives Second €6M Tranche Disbursement From the European Investment Bank (EIB)
    PR Newswirelast month

    BiondVax Receives Second €6M Tranche Disbursement From the European Investment Bank (EIB)

    NESS ZIONA, Israel, Aug. 14, 2018  /PRNewswire/ --- BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of a €6 million disbursement from the European Investment Bank (EIB). The first tranche of €6 million was received by BiondVax in June 2018[2]. Funds will be advanced in three tranches.

  • First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
    PR Newswirelast month

    First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

    The primary endpoints of the trial are to demonstrate protection from influenza and safety of M-001. A secondary endpoint will assess reduction in flu illness severity among those receiving M-001 versus placebo. In six completed clinical trials in Israel and Europe (two Phase 1/2 and four Phase 2), M-001 has been shown to be safe, well-tolerated, and immunogenic to a broad range of influenza strains.

  • Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
    PR Newswire3 months ago

    Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors

    NESS ZIONA, Israel, June 28, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase Universal Influenza Vaccine candidate, announced today the appointment of Mr. Mark Germain as Vice-Chairman of its Board of Directors. Based in New York, and having served as founder, director, chairman of the board, and/or investor in over twenty biotech companies, and with experience assisting in arranging corporate partnerships, acquiring technology, entering mergers and acquisitions, and executing financings, Mr. Germain is well suited to help guide BiondVax's ongoing corporate development. Mr. Mark Germain commented, "I am pleased and excited to join the BiondVax board at this important time in the development of the company.

  • BiondVax Receives Its First €6M Tranche Disbursement From the European Investment Bank (EIB)
    PR Newswire3 months ago

    BiondVax Receives Its First €6M Tranche Disbursement From the European Investment Bank (EIB)

    NESS ZIONA, Israel, June 19, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase Universal Influenza Vaccine candidate, announced today the receipt of a €6 million disbursement from the European Investment Bank (EIB). Dr. Ron Babecoff, BiondVax's President and CEO, commented, "We plan to begin our first pivotal, clinical efficacy, Phase 3 trial later this year, while the construction of our mid-size commercial manufacturing facility is well underway. "We are grateful for the excellent ongoing collaboration and relationship with the EIB towards the development of our universal flu vaccine," continued Babecoff.

  • Zacks Small Cap Research4 months ago

    BVXV: Increased Media Coverage for M-001 Ahead of Phase 3 Clinical Trial

    BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has received feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).

  • BiondVax Announces First Quarter 2018 Financial Results
    PR Newswire4 months ago

    BiondVax Announces First Quarter 2018 Financial Results

    NESS ZIONA, Israel , May 29, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...

  • Zacks Small Cap Research4 months ago

    BVXV: Set to Initiate Phase 3 Clinical Trial of Universal Influenza Vaccine Candidate in 2H18

    BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has received feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).

  • BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update
    PR Newswire5 months ago

    BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update

    NESS ZIONA, Israel , April 30, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal ...

  • ACCESSWIRE5 months ago

    Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US

    Stock Monitor: Dare Bioscience Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on BiondVax Pharma Ltd (NASDAQ: BVXV ) (''BiondVax''). ...

  • BiondVax to Present at Universal Influenza Vaccines Conference
    PR Newswire5 months ago

    BiondVax to Present at Universal Influenza Vaccines Conference

    NESS ZIONA, Israel , April 12, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal flu vaccine candidate M-001, reported today it will present at the Universal ...

  • PR Newswire5 months ago

    BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States

    NESS ZIONA, Israel , April 11, 2018 /PRNewswire/ --   BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) reported today the first participant enrollment in the United States in a Phase 2 clinical trial of the ...

  • BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate
    PR Newswire6 months ago

    BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate

    NESS ZIONA, Israel, March 13, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (BVXV), developer of the Universal Flu Vaccine candidate M-001, announced today the signing of a Master Service Agreement (MSA) with a contract research organization (CRO) to conduct the first pivotal, clinical efficacy, Phase 3 trial of M-001. BiondVax's pivotal, clinical efficacy, Phase 3 trial is planned to begin later this year, prior to the 2018/19 Northern Hemisphere flu season.

  • BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference
    PR Newswire7 months ago

    BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference

    NESS ZIONA, Israel, Feb. 8, 2018 /PRNewswire/ --BiondVax Pharmaceuticals Ltd. (BVXV), developer of a Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, and the European UNISEC consortium announced today they will co-host the Annual UNISEC Consortium Meeting, which will take place next week in Jerusalem, Israel. Attendees representing the consortium's partners from academia, government, and industry will discuss achievements towards development of a universal influenza vaccine, including the recent successful results of the Phase 2b clinical trial on BiondVax's universal flu vaccine candidate M-001. Also expected to attend will be representatives from the U.S. Department of Health and Human Services (HHS).

  • BiondVax Universal Flu Vaccine Patent Granted in India
    PR Newswire9 months ago

    BiondVax Universal Flu Vaccine Patent Granted in India

    NESS ZIONA, Israel, Jan. 2, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) (BVXV), developer of M-001, the Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, announced today that one of its key patents titled "A Synthetic or Recombinant Influenza Multi-Epitope Polypeptide" has been granted in India. The patent belongs to BiondVax's portfolio family titled "Multimeric Multi-Epitope Influenza Vaccines" and has now been granted in over 30 countries. With a population of over 1.3 billion people, and high population density in some of the major cities, India is an important potential market for BiondVax and a universal flu vaccine may significantly improve public health.

  • BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)
    PR Newswire9 months ago

    BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)

    NESS ZIONA, Israel, Dec. 27, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV) announced today that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) reviewed BiondVax's Phase 3 trial plan, provided advice, and allowed the Company to proceed with the Phase 3 clinical trial plan for M-001, BiondVax's universal flu vaccine candidate. Babecoff continued, "There is a clear need to improve upon current flu vaccine technologies, as noted in the recent New England Journal of Medicine article titled Chasing Seasonal Influenza — The Need for a Universal Influenza Vaccine.[1]  BiondVax's Universal Flu Vaccine candidate is designed to address challenges of current flu vaccines such as mismatches, mutations, and long production lag.

  • Zacks Small Cap Research9 months ago

    BVXV: Planning Continues for M-001 Phase 3 Program …

    BiondVax’s (BVXV) strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has already initiated discussions with the European Medicines Agency (EMA) regarding the trial design. The trial is being conducted in Eastern Europe since there are not recommendations in some of those countries to get the yearly influenza vaccine, thus making it much easier to enroll sufficient numbers of subjects who have not been previously immunized with the yearly influenza vaccine.

  • ACCESSWIRE9 months ago

    Blog Exposure - Synlogic And Ginkgo Bioworks Collaborate to Discover and Develop New Medicines for Neurological and Liver Disorders

    Stock Monitor: BiondVax Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 11, 2017 / Active-Investors issued a free report on Synlogic, Inc. (NASDAQ: SYBX ), which is readily accessible ...